Scalable Downstream Strategies for Purification of Recombinant Adeno-Associated Virus Vectors in Light of the Properties

被引:50
|
作者
Qu, Weihong [1 ,2 ,3 ,4 ]
Wang, Mingxi [1 ,2 ,3 ]
Wu, Yaqing [1 ,2 ,3 ]
Xu, Ruian [1 ,2 ,3 ]
机构
[1] Huaqiao Univ, Sch Med, Yunleung Lab Mol Diagnost, Quanzhou 362021, Peoples R China
[2] Huaqiao Univ, Inst Mol Med, Quanzhou 362021, Peoples R China
[3] Minist Educ, Engn Res Ctr Mol Med, Xiamen 361021, Peoples R China
[4] Jiujiang Univ, Coll Med & Life Sci, Jiujiang 332000, Jiangxi, Peoples R China
基金
中国国家自然科学基金;
关键词
Clinical application; downstream purification; large scale; physicochemical properties; purification strategy; rAAV vector; ION-EXCHANGE CHROMATOGRAPHY; LIPOPROTEIN-LIPASE DEFICIENCY; SERUM-FREE PRODUCTION; HUMAN GENE-THERAPY; VIRAL VECTORS; HIGH-TITER; COLUMN CHROMATOGRAPHY; EMPTY CAPSIDS; LARGE-SCALE; IN-VIVO;
D O I
10.2174/1389201016666150505122228
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Recombinant adeno-associated virus (rAAV) vector is one of the promising delivery tools for gene therapy. Currently, hundreds of clinical trials are performed but the major barrier for clinical application is the absence of any ideal large scale production technique to obtain sufficient and highly pure rAAV vector. The large scale production technique includes upstream and downstream processing. The upstream processing is a vector package step and the downstream processing is a vector purification step. For large scale downstream processing, the scientists need to recover rAAV from dozens of liters of cell lysate or medium, and a variety of purification strategies have been developed but not comprehensively compared till now. Consequently, this review will evaluate the scalable downstream purification strategies systematically, especially those based on the physicochemical properties of AAV virus, and attempt to find better scalable downstream strategies for rAAV vectors.
引用
收藏
页码:684 / 695
页数:12
相关论文
共 50 条
  • [31] Systemic Toxicity of Recombinant Adeno-Associated Virus Gene Therapy Vectors
    Assaf, Basel T.
    TOXICOLOGIC PATHOLOGY, 2024, 52 (08) : 523 - 530
  • [32] Novel strategy for generation and titration of recombinant adeno-associated virus vectors
    Shiau, AL
    Liu, PS
    Wu, CL
    JOURNAL OF VIROLOGY, 2005, 79 (01) : 193 - 201
  • [33] Orthopaedic gene therapy using recombinant adeno-associated virus vectors
    Ke, J.
    Zheng, L. W.
    Cheung, L. K.
    ARCHIVES OF ORAL BIOLOGY, 2011, 56 (07) : 619 - 628
  • [34] Clinical gene therapy using recombinant adeno-associated virus vectors
    Mueller, C.
    Flotte, T. R.
    GENE THERAPY, 2008, 15 (11) : 858 - 863
  • [35] Recombinant adeno-associated virus vectors for cystic fibrosis gene therapy
    Flotte, TR
    CURRENT OPINION IN MOLECULAR THERAPEUTICS, 2001, 3 (05) : 497 - 502
  • [36] Targeting recombinant adeno-associated virus vectors to enhance gene transfer
    Loiler, SA
    Song, SH
    Warrington, KH
    Agarwal, A
    Kapturczak, M
    Li, CW
    Ricordi, C
    Atkinson, MA
    Muzyczka, N
    Flotte, TR
    PEDIATRIC RESEARCH, 2003, 53 (04) : 133A - 134A
  • [37] Genetic Vaccines for Anthrax Based on Recombinant Adeno-associated Virus Vectors
    Liu, Te-Hui
    Oscherwitz, Jon
    Schnepp, Bruce
    Jacobs, Jana
    Yu, Fen
    Cease, Kemp B.
    Johnson, Philip R.
    MOLECULAR THERAPY, 2009, 17 (02) : 373 - 379
  • [38] Clinical gene therapy using recombinant adeno-associated virus vectors
    C Mueller
    T R Flotte
    Gene Therapy, 2008, 15 : 858 - 863
  • [39] Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
    Motahareh Arjomandnejad
    Ishani Dasgupta
    Terence R. Flotte
    Allison M. Keeler
    BioDrugs, 2023, 37 : 311 - 329
  • [40] Production of clinical-grade recombinant adeno-associated virus vectors
    Snyder, RO
    Flotte, TR
    CURRENT OPINION IN BIOTECHNOLOGY, 2002, 13 (05) : 418 - 423